MAIA doses first patient in Phase 2 expansion for ateganosine in advanced NSCLC; median OS 17.8 months

MAIA Biotechnology, Inc.

First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.
Median overall survival of 17.8 months observed in 22 patients (95% CI lower bound 12.5 months) in third-line setting.
Expansion includes two arms: ateganosine+cemiplimab (Libtayo) and monotherapy; screening in Europe/Asia.
Regeneron supplies Libtayo for combination cohort.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.